Core Viewpoint - CytomX is focused on advancing its unique Probody therapeutic platform in oncology, aiming to enhance the therapeutic window of treatments [2][3]. Company Overview - CytomX is a South San Francisco-based biotech company specializing in oncology, with over 15 years of experience in developing and optimizing its Probody therapeutic platform [3]. Pipeline Development - The company is committed to building a highly differentiated pipeline, with expectations for continued progress in 2026 following a successful 2025 [2].

Core Insights - CytomX is an oncology-focused biologics company that has developed a unique Probody therapeutic platform aimed at improving the therapeutic window for potent anticancer agents [1] - The company has pioneered the concept of antibody masking, which has been in development for approximately 15 years [1] - CytomX is currently advancing two clinical programs: CX-2051, an EpCAM-targeted masked antibody-drug conjugate, and CX-801, a masked version of interferon alpha-2b [1]

Core Insights - CytomX is an oncology-focused biologics company that has developed a unique Probody therapeutic platform aimed at improving the therapeutic window for potent anticancer agents [1] - The company has pioneered the concept of antibody masking, which has been in development for approximately 15 years [1] - CytomX is currently advancing two clinical programs: CX-2051, an EpCAM-targeted masked antibody-drug conjugate, and CX-801, a masked version of interferon alpha-2b [1]